-

Transgene: Balance Sheet of the Liquidity Contract with Natixis Oddo BHF SCA as of December 31, 2021

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:

Under the liquidity contract entrusted by Transgene (Paris:TNG) to Natixis Oddo BHF SCA, as of December 31, 2021, the following resources were managed through the liquidity account:

- 176,500 shares

- € 334,853.00

In the second half of 2021, a total of:

Purchases

434,514 shares

€ 1,060,091

849 market transactions

Sales

433,014 shares

€ 1,082,327

902 market transactions

It is recalled that when the liquidity program was initially established in 2016, the following resources were made available:

Cash balance of the liquidity contract: € 500,000.00

At the time the liquidity program was transferred to Natixis Oddo BHF SCA on January 2, 2020, the resources managed through the liquidity account consisted of:

- 164,183 shares

- € 246,158.00

Contacts

Transgene:

Jean-Philippe Del
CFO
+33 (0)3 88 27 91 00
investorrelations@transgene.fr

Transgene

BOURSE:TNG
Release Versions
EnglishFrench

Contacts

Transgene:

Jean-Philippe Del
CFO
+33 (0)3 88 27 91 00
investorrelations@transgene.fr

More News From Transgene

Transgene Announces Upcoming Investor Meetings

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: TRANSGENE (Paris:TNG) today announces that Management will participate in several investor events in the upcoming investor events, as set out below. Transgene will meet institutional investors at the 13th Annual LifeSci Advisors Corporate Access Event in San Francisco from January 8 to 10, 2024, in conjunction with the J.P. Morgan Healthcare conference. The Company will also attend: 27th ODDO BHF Forum (virtual): January 15-16, 2024; Invest...

Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of Arnaud Dubarry as Chief Financial Officer (CFO), effective January 1, 2024. Arnaud Dubarry will be based in Strasbourg and will be responsible for all aspects of the Company’s financial strategy, management and operations to accelerate the development of it...

Transgene Reports Business Update and Q3 2023 Financial Position

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business update and its financial position for the quarter ending September 30, 2023. During the third quarter of 2023, Transgene’s clinical-stage immunotherapy portfolio continued to advance. Notable progress included the treatment of the first patient in the Part B of Phase I trial assess...
Back to Newsroom